Nasal spray shows promise for Hard-to-Control asthma
NCT ID NCT05985694
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study tested whether an intranasal immunomodulator called AD17002 can help people with poorly controlled moderate to severe eosinophilic asthma. Forty adults self-administered the spray or a placebo twice a week for six weeks. Researchers measured lung function, rescue inhaler use, and safety to see if the treatment improves asthma control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan
Conditions
Explore the condition pages connected to this study.